Cell & Gene Therapy Companies
Developers of autologous and allogeneic cell therapies, viral vector gene therapies, and gene editing platforms for cancer, genetic disorders, and degenerative diseases.
Market snapshot
These figures describe Biotech & Biopharmaceuticals (4.9.1), the segment that Cell & Gene Therapy Companies sits within — not Cell & Gene Therapy Companies on its own.
- Market size
- ~$211B
- Growth
- ~1.4%CAGR (2017–22, nominal)
- Companies
- ~2,600
U.S. Census Bureau 2022 CBP/Economic Census, NAICS 325411 + 325412 + 325414 (pharmaceutical/biological manufacturing) — U.S. manufacturing receipts; the global, IP-driven market is far larger.
Business model & economics
Revenue model
Patent-protected drug sales and royalties
Key economics
- Recurring revenue
- Moderate
- EBITDA margin
- High for branded on-patent drugs
- Capex intensity
- High
on-patent franchises; cliffs reset it
Characteristics
- The innovation engine of healthcare — high-risk, R&D-intensive.
- Patent cliffs drive constant pipeline-replenishing M&A.
- GLP-1/obesity franchise reshaped sector growth.
Geographic concentration
Biotech and biopharmaceutical operations concentrate in the established life-sciences clusters — California (the Bay Area and San Diego), Massachusetts (Greater Boston), and North Carolina's Research Triangle — by far the largest centers of industry employment.
U.S. Census Bureau — 2022 County Business Patterns (employment by state), NAICS 325411/325412/325414. Leading states by biopharmaceutical employment.
M&A deal context
Who’s acquiring
- Big pharma & biopharma strategics
- Biotech-acquiring platforms
- VC- and crossover-backed biotech
What’s driving deals
- Patent-cliff-driven acquisition of biotech pipelines.
- GLP-1 and novel-modality competition.
- Biotech funding cycles and platform deals.
Find Cell & Gene Therapy Companies acquisition targets
Search Acquisera’s index for companies classified under Cell & Gene Therapy Companies (4.9.1.2) and build a targeted deal pipeline.
Search companies